Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Neuroblastoma 1Medulloblastoma 1Lymphoma 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Radiosurgery 114Temozolomide 104Bevacizumab 71Radiotherapy 67Magnetic Resonance Spectroscopy 67Carboplatin 29pembrolizumab 28Irinotecan 26Surgical Procedures, Operative 25Radiation 23Nivolumab 23Etoposide 22Magnetic Resonance Imaging 21Ipilimumab 21Erlotinib Hydrochloride 21Cyclophosphamide 21Surveys and Questionnaires 19Aminolevulinic Acid 18Specimen Handling 16Pemetrexed 16Mental Status and Dementia Tests 16Cisplatin 16Carmustine 15Topotecan 14Trastuzumab 13Saline Solution 12Neuropsychological Tests 12Gefitinib 11Filgrastim 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Brain Neoplasms × CUDC-907 × Clear all
NCT02909777 2026-02-11

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

Dana-Farber Cancer Institute

Phase 1 Completed
26 enrolled
CNSLymphoid

Brain Neoplasms, Lymphoma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡